Explore
Validate
Learn
ELISA
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB633 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TRAILR4/TNFRSF10D Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from ascites. Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF-alpha , and rhTNF-beta is observed.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
Q9UBN6- Isotype
- IgG
- Antibody clone number
- 104918
- Vial size
- 500 ug
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N
PloS one 2018;13(6):e0198203
PloS one 2018;13(6):e0198203
Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
Neumann S, Hasenauer J, Pollak N, Scheurich P
The Journal of biological chemistry 2014 Jun 6;289(23):16576-87
The Journal of biological chemistry 2014 Jun 6;289(23):16576-87
TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L
Anticancer research 2014 Feb;34(2):729-34
Anticancer research 2014 Feb;34(2):729-34
TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL
Cancer gene therapy 2012 Sep;19(9):652-8
Cancer gene therapy 2012 Sep;19(9):652-8
Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
Journal of cellular physiology 2010 Feb;222(2):357-64
Journal of cellular physiology 2010 Feb;222(2):357-64
Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G
Blood 2009 Oct 29;114(18):3854-63
Blood 2009 Oct 29;114(18):3854-63
Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
Stem cells (Dayton, Ohio) 2008 Nov;26(11):2955-63
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
Journal of cellular biochemistry 2008 May 15;104(2):595-605
Journal of cellular biochemistry 2008 May 15;104(2):595-605
P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
Oncogene 2008 Jul 10;27(30):4161-71
Oncogene 2008 Jul 10;27(30):4161-71
Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
Molecular cancer therapeutics 2008 Aug;7(8):2328-38
Molecular cancer therapeutics 2008 Aug;7(8):2328-38
A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
Cell death and differentiation 2008 Apr;15(4):718-29
Cell death and differentiation 2008 Apr;15(4):718-29
Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Dürkop H, Sterry W, Eberle J
The Journal of investigative dermatology 2007 Oct;127(10):2425-37
The Journal of investigative dermatology 2007 Oct;127(10):2425-37
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
Molecular cancer therapeutics 2007 Dec;6(12 Pt 1):3219-28
Molecular cancer therapeutics 2007 Dec;6(12 Pt 1):3219-28
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
Singh TR, Shankar S, Srivastava RK
Oncogene 2005 Jul 7;24(29):4609-23
Oncogene 2005 Jul 7;24(29):4609-23
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50 is typically 0.3-1.8 µg/mL.
